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Despite the tremendous efforts and budgets 
invested in the war on cancer, the outcome has 
been rather limited, to say the least, except for 
a number of specific cancers, such as testicular 
cancer, Hodgkin’s lymphoma and several types 
of leukemia with cure rates in excess of 90%. 
In spite of these specific successes, cancer is 
estimated to become the leading cause of death 
worldwide in 2010, according to the International 
Agency for Research on Cancer (IARC), a divi-
sion of the WHO. The targets used for drug 
development have been largely nonspecific and, 
thus, cancer treatment has led, in several cases, 
to serious short- or long-term toxic side effects. 
The rather modest progress in the chemotherapy 
of cancer over the last 60 years suggests that some 
of the frameworks used for targeting the malig-
nant cell are wrong, or at least not totally correct. 
Perception of the cancer cell as having only an 
uncontrolled proliferation is one such framework. 
Antiproliferative drugs have had only a modest 
impact in the clinic. This is not surprising, since 
many tumors have a low growth rate. Thus, there 
is an urgent need to search for new ways to target 
the tumor cell more efficiently, and to develope 
new drugs to overcome the rather poor return of 
current cancer chemotherapy.
Defects in apoptosis are a major hallmark of 
cancer, and contribute to drug resistance and 
poor outcomes in patient treatment [1,2]. Since 
the final goal in cancer therapy is to get rid of 
tumor cells, an appealing approach would be to 
set in motion the apoptotic machinery of the 
cancer cell to induce its own demise. Thus, direct 
activation of the cancer cell apoptotic arsenal 
constitutes an appealing therapy for the treat-
ment of cancer that would be independent of 
the cell cycle and of frequently mutated tumor 
suppressor genes in cancer.
A remarkable trait of mammalian cells lies in 
the presence of death receptors at their plasma 
membrane. Once activated, these death recep-
tors trigger apoptosis signaling and, hence, they 
can regulate cell death. This opens an interesting 
approach for therapeutic intervention. Cells may 
commit suicide if they are being encouraged to 
do it. By modulating the apoptosis machinery of 
the cancer cell, it should be feasible to enforce 
its own cell death. Thus, this apoptosis-targeted 
therapy could foster an effective destruction 
of the tumor. Unlike other cellular processes, 
proteins involved in apoptosis, such as death 
receptors (e.g., Fas/CD95) and adaptor proteins 
(e.g., FADD), lack intrinsic enzymatic activity but 
largely depend on protein–protein interactions to 
convey apoptotic signals through the assembly of 
major apoptotic complexes. One of these com-
plexes is the death-inducing signaling complex [3], 
made up of Fas/CD95, FADD and procaspase-8, 
which leads to the high local concentration of pro-
caspase-8 molecules and its subsequent proteolytic 
activation by close proximity. In this regard, the 
concentration of apoptotic molecules in a limited 
region of the cell would favor the generation of 
apoptotic complexes and, consequently, apoptosis.
“Defects in apoptosis are a major 
hallmark of cancer, and contribute to 
drug resistance and poor outcomes in 
patient treatment.”
Lipid rafts & death receptor signaling
Recent evidence shows that sphingolipid- and 
cholesterol-rich membrane microdomains, named 
‘lipid rafts’, serve as platforms for the recruitment 
and concentration of apoptotic signaling mol-
ecules at the plasma membrane [4–7]. In 2001, we 
Lipid rafts, death receptors 
and CASMERs: new insights for 
cancer therapy
“Since the final goal in cancer therapy 
is to get rid of tumor cells, an appealing 
approach would be to set in motion 
the apoptotic machinery of the cancer 
cell to induce its own demise.”
Faustino Mollinedo† & Consuelo Gajate
†Author for correspondence: Instituto de Biología Molecular y Celular del Cáncer, Centro de Investigación 
del Cáncer, CSIC-Universidad de Salamanca, Campus Miguel de Unamuno, E-37007 Salamanca, Spain 
n Tel.: +34 923 294 806 n Fax: +34 923 294 795 n fmollin@usal.es
Ed
ito
ria
l
For reprint orders, please contact: reprints@futuremedicine.com
Future Oncol. (2010) 6(4)492 future science group
Editorial Mollinedo & Gajate
found that the antitumor alkyl- lysophospholipid 
analog edelfosine (1-O-octadecyl-2-O-methyl-
rac-glycero-3-phosphocholine; ET-18-OCH
3
) 
induced tumor cell killing through co-cluster-
ing of Fas/CD95 death receptor in lipid rafts [8]. 
Subsequent studies showed that edelfosine 
induced translocation of additional apoptotic 
downstream signaling molecules into membrane 
rafts, including FADD, procaspase-8, procas-
pase-10, BH3-interacting domain death agonist 
(Bid), JNK and apoptosome constituents [4,7,9–11]. 
The co-clustering of Fas/CD95 death receptor 
and lipid rafts was independent of its cognate 
natural ligand and could be modulated phar-
macologically [4]. This latter aspect opens up 
a promising approach in cancer treatment, as 
the recruitment of apoptotic molecules in rafts 
may become an emerging target for therapeutic 
intervention. In fact, following the pioneering 
work with edelfosine [8], a growing number of 
antitumor agents are being reported to promote 
apoptosis of cancer cells through co-clustering of 
Fas/CD95 death receptor and lipid rafts, includ-
ing aplidin, cisplatin, perifosine, resveratrol and 
rituximab [9,12–16]. 
Additional death receptors, particularly TNF-
related apoptosis-inducing ligand (TRAIL) 
receptors, have also been reported to be translo-
cated to lipid rafts during the induction of apop-
tosis [9,12,15,17]. The co-aggregation of distinct 
death receptors and rafts sensitizes cancer cells 
to their cognate ligands [9,17]. In this context, 
TRAIL shows an encouraging antitumor activ-
ity and is currently in clinical trials [18–20]; treat-
ment of multiple myeloma cells with edelfosine 
and perifosine, which promote death receptor-
enriched raft clusters [9], sensitizes these cancer 
cells to the action of TRAIL [9,21].
CASMER & cancer therapy 
Since accumulating evidence indicates that 
the clustering of apoptotic molecules in lipid 
rafts is a general process involved in apopto-
sis, we have coined the word ‘CASMER’ as 
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Figure 1. CASMER formation in cancer treatment. A number of antitumor agents (discussed in the article) induce clusters of plasma 
membrane lipid rafts, which are enriched in a variable number of death receptors and downstream apoptotic signaling molecules 
(i.e., CASMER). This recruitment of death receptors and apoptotic molecules in raft clusters, leading to the formation of CASMERs, 
promotes the generation of apoptosis-prone platforms or membrane compartments that eventually results in the death of the cancer cell 
by apoptosis.  
Bid: BH3-interacting domain death agonist; CASMER: Cluster of apoptotic signaling molecule-enriched rafts.
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an acronym of ‘cluster of apoptotic signaling 
molecule-enriched rafts’ [4,11,12] to refer to this 
recruitment of death receptors together with 
downstream apoptotic signaling molecules in 
aggregated rafts (Figure 1). CASMER represents 
a novel lipid-raft-based supramolecular entity 
that seems to play a critical role in the regula-
tion of apoptosis, acting as a death-promoting 
scaffold where death receptors and downstream 
signaling molecules are brought together, thus 
facilitating protein–protein interactions and the 
transmission of apoptotic signals.
“... CASMER may form an Achilles’ heel 
for cancer cells.”
The ability to generate CASMERs, as well 
as their protein composition, depends on both 
the cell phenotype and the triggering stimu-
lus [4,9,12,15]. Cholesterol is a critical constitu-
ent of lipid rafts, and its displacement disrupts 
CASMERs [4,7–9]. This is of particular interest, 
as cancer cells have been reported to be enriched 
in cholesterol [22,23]; and to display higher levels 
of cholesterol-rich lipid rafts than their normal 
counterparts [24]. On these grounds, it could be 
envisaged that cancer cells might potentially 
be prone to form CASMERs, thus becoming 
a convenient therapeutic target. In this way, 
CASMER may form an Achilles’ heel for cancer 
cells. The recruitment of part of the apoptotic 
machinery of tumor cells in rafts, forming the 
CASMERs, from which apoptotic signals are 
launched, leading eventually to cell death, makes 
cancer cells more vulnerable.
Since CASMER formation directly trig-
gers the apoptotic machinery, the potential for 
CASMER-based therapies seems very promising 
in the treatment of cancer and other patholo-
gies where the stimulation of apoptosis is defec-
tive. We are entering an exciting area in which 
novel frameworks in apoptosis-targeted therapy 
may improve efficiency in cancer treatment. 
CASMER-mediated direct activation of apopto-
sis opens a new avenue in cancer therapy, which 
would be independent of tumor suppressor genes 
(e.g., p53) that are frequently mutated in can-
cer. The concept of CASMER is also related to 
the notion of subcellular compartmentalization 
of biological processes. CASMERs act as scaf-
folds for the recruitment of apoptotic molecules, 
and this highlights the existence of platforms 
or membrane compartments, where proteins 
specialized in apoptosis are brought together to 
facilitate their physical interaction in order to 
prompt a potent apoptotic response. 
The mechanism of action of the phospholipid 
ether edelfosine can be considered as the para-
digm for this new CASMER-mediated anti cancer 
therapeutic approach. The elucidation of how 
this drug promotes cancer cell killing through 
CASMER formation should aid the design of 
new and more effective anticancer drugs.
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